SCHEMBL17134922

SCHEMBL17134922

COC(=O)C1(c2ccccc2)CCN(C(=O)c2cnc(S(N)(=O)=O)c(Cl)c2Nc2cccc(C)c2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CSF1R P07333 1/20 0.38
▸ HSD11B1 P28845 1/20 0.38
▸ OPRD1 P41143 1/20 0.37
▸ AURKB Q96GD4 3/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ ADRA1D P25100 3/20 0.36
▸ ADRA1A P35348 3/20 0.36
▸ ADRA1B P35368 2/20 0.36
▸ PDE4A P27815 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4C Q08493 1/20 0.36
▸ PDE4D Q08499 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135019 0.93 CNR2 (0.40) CA12CA1CA2CA7CA9
SCHEMBL17134741 0.86 ALDH1A1 (0.42) CA12CA1CA2CA7CA9
SCHEMBL17135113 0.84 MAPT (0.37) CA2KDM4ERAB9ACSF1RAURKB
SCHEMBL17134905 0.83 POLB (0.42) KDM4ERAB9ACSF1RAURKBALDH1A1
SCHEMBL17134930 0.82 PKLR (0.41) CA12CA1CA2CA7CA9
SCHEMBL17292884 0.82 DRD4 (0.44) CA12CA1CA2CA7CA9
SCHEMBL17134840 0.79 KDM4E (0.36) KDM4ERAB9ACSF1RAURKBALDH1A1
SCHEMBL17134773 0.78 CSF1R (0.45) CA12CA1CA2CA9CSF1R
SCHEMBL17134855 0.77 DRD4 (0.41) KDM4ERAB9AHSD11B1ALDH1A1MAPT
SCHEMBL17134786 0.77 CNR2 (0.39) CA2CSF1RPDE4BPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR CA12 1854/4885CA1 2565/4885CA2 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback